Exscientia has advanced a drug candidate for Alzheimer's disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based drug discov
Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started testing of the first AI candidate for
Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease.
Drug discovery firm Exscientia has beefed up its leadership team with the appointment of former AstraZeneca scientist Dr Garry Pairaudeau as its chief technology officer.
US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery.
A record number of health and medtech companies have been included in the Sunday Times Sage Tech Track 100, which ranks Britain’s private tech companies.